Dermisonics, Inc.
Dermisonics, Inc.: Financial and Operations Veteran Joins Dermisonics Board of Directors
Corporate-news transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
——————————————————————————
Financial and Operations Veteran
Joins Dermisonics Board of Directors
Irvine, California — March 27, 2006 (PR Newswire)
Dermisonics, Inc. (OTC Bulletin Board: DMSI.OB), a pioneer in the
development of painless injection-free ultrasonic transdermal drug-delivery
technologies with broad pharmaceutical and consumer applications, announced
today that it had appointed Grant Atkins to its Board of Directors.
Mr. Atkins, currently President and Director Lexington Resources, Inc., an
oil and gas exploration and development company, has a fifteen-year
entrepreneurial record of success with extensive multi-industry credentials
in the fields of finance, administration and business development. His
previous industry experience includes:
– Biotech cancer immunotherapy (GeneMax Corp.), CFO
– Gold mining and silver and zinc exploration in China (Vega-Atlantic
Corporation), President
– Electronic Data Processing (Transax International Limited), Director,
and
– A $200 million (CDN funds) radio and tri-service dispatch initiative
and deployment of Canadian federal, provincial and municipal
shareholders as interim Chief Financial Officer of Emergency
Communications for Southwest British Columbia (‘E-Comm’).
Mr. Atkins has extensive public company governance and operational
experience handling all aspects relating to public company finance and
administration including SEC filings, registration statements, financial
statement preparation, audit liaison, audit and ethics committee operation,
proxy statement and annual meeting, business planning, cash flow controls,
Sarbanes Oxley compliance, trading dynamics, and investor relations. He is
a Graduate of University of British Columbia with a Bachelors of Commerce
Degree.
Bruce Haglund, CEO of Dermisonics, commented, “Grant’s extensive financial
and operations experience at the most senior management levels coupled with
his entrepreneurial mindset will be a major asset in our drive to exploit
the rich applications potential of Dermisonic’s technology in the drug,
cosmetic and antiseptic industries.”
About Dermisonics, Inc. – Dermisonics is an intellectual property company
and advanced technology incubator that is primarily focused on developing
and marketing its transdermal and subdermal technologies for applications
in the drug (U-Strip), skin care (U-Wand), and antiseptic (A-Wand) fields.
Its breakthrough system, called the U-Strip, facilitates the efficient and
needle-free delivery of drugs with large molecular structures into the
bloodstream. This system is based on a radical integration of
microelectronics and ultrasonic science with a product-carrying patch and
represents a quantum leap in non-invasive, transdermal delivery technology.
Tests have shown that the U-Strip facilitates the transdermal delivery of
Insulin as well as potentially at least 175 other existing drugs through
the pores of the skin. Conventionally available transdermal technology
cannot effectively deliver these drugs due to their large molecular size.
The Company has also developed major line extensions for applications in
the medical (Antiseptic Wand) and skin care (U-Wand) fields.
For further information contact Bruce Haglund, CEO.
bruce.haglund@dermisonics.com
Dermisonics, Inc.
Jamboree Center
2 Park Plaza, Suite 450
Irvine, California 92614
888-401-DERM (3376) Toll Free
(949) 733-1101 Phone
(949) 266-8426 Fax
Web site: www.Dermisonics.com
North American Investor Relations Contact:
Brent Pierce, International Marketing Trend, Inc.
Phone: 877-676-4447
brent@brentpierce.com
European Investor Relations Contact:
Michael Drepper
Phone: +49-621-430-6130
investor-germany@dermisonics.com
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 that are based upon current expectations or beliefs,
as well as a number of assumptions about future events. Although the
Company believes that the expectations reflected in the forward-looking
statements and the assumptions upon which they are based are reasonable, it
can give no assurance that such expectations and assumptions will prove to
have been correct. The reader is cautioned not to put undue reliance on
these forward-looking statements, as these statements are subject to
numerous factors and uncertainties, including but not limited to adverse
economic conditions, intense competition, lack of meaningful research
results, entry of new competitors and products, adverse federal, state and
local government regulation, inadequate capital, unexpected costs and
operating deficits, increases in general and administrative costs,
termination of contracts or agreements, technological obsolescence of the
Company’s products, technical problems with the Company’s research and
products, price increases for supplies and components, litigation and
administrative proceedings involving the Company, the possible acquisition
of new businesses or that result in operating losses or that do not
perform as anticipated, unanticipated losses, the possible fluctuation and
volatility of the Company’s operating results, financial condition and
stock price, losses incurred in litigating and settling cases, dilution in
the Company’s ownership of its business, adverse publicity and news
coverage, inability to carry out research, development and
commercialization plans, loss or retirement of key executives and research
scientists, changes in interest rates, inflationary factors, and other
specific risks. In addition, other factors that could cause actual results
to differ materially are discussed in the Company’s most recent Form 10-QSB
and Form 10-KSB filings with the Securities and Exchange Commission.
(c)DGAP 27.03.2006
—————————————————————————
language: English
emitter: Dermisonics, Inc.
Dermisonics, Inc.
19428-2977 West Conshohocken, Pa. Vereinigte Staaten von Amerika
phone: +1 610-941-2780
fax: +1 610-941-2990
email: bruce.haglund@dermisonics.com
WWW: dermisonics.com
ISIN: US24983U1043
WKN: A0DK4Y
indexes:
stockmarkets: Freiverkehr in Berlin-Bremen; Open Market in Frankfurt
End of News DGAP News-Service
—————————————————————————
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found